about
Three decades of beta-lactamase inhibitorsEscherichia coli β-Lactamases: What Really MattersBeyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-LactamasesTreatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients.Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.Analysis of β-lactamase phenotypes and carriage of selected β-lactamase genes among Escherichia coli strains obtained from Kenyan patients during an 18-year period.Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended- spectrum-beta-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction.Molecular Analysis of Antibiotic Resistance Determinants and Plasmids in Malaysian Isolates of Multidrug Resistant Klebsiella pneumoniae.In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.The Complete Sequence and Comparative Analysis of a Multidrug-Resistance and Virulence Multireplicon IncFII Plasmid pEC302/04 from an Extraintestinal Pathogenic Escherichia coli EC302/04 Indicate Extensive Diversity of IncFII PlasmidsAntibiotics as selectors and accelerators of diversity in the mechanisms of resistance: from the resistome to genetic plasticity in the β-lactamases worldA Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes.Detection of resistance to beta-lactamase inhibitors in strains with CTX-M beta-lactamases: a multicenter external proficiency study using a well-defined collection of Escherichia coli strains.Proliferation and significance of clinically relevant β-lactamases.In vitro selection of variants resistant to beta-lactams plus beta-lactamase inhibitors in CTX-M beta-lactamases: predicting the in vivo scenario?Integrated detection of extended-spectrum-beta-lactam resistance by DNA microarray-based genotyping of TEM, SHV, and CTX-M genesHomology modeling and virtual screening of inhibitors against TEM- and SHV-type-resistant mutants: A multilayer filtering approach.Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTScreening of inhibitors for S130G inhibitor resistant mutants of TEM type beta-lactamase.Population analysis and epidemiological features of inhibitor-resistant-TEM-beta-lactamase-producing Escherichia coli isolates from both community and hospital settings in Madrid, Spain.BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.Impact of Mutations at Arg220 and Thr237 in PER-2 β-Lactamase on Conformation, Activity, and Susceptibility to Inhibitors.Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).Bismuth antimicrobial drugs serve as broad-spectrum metallo-β-lactamase inhibitors.Genetic and Functional Characterization of blaCTX-M-199, a Novel Tazobactam and Sulbactam Resistance-Encoding Gene Located in a Conjugative mcr-1-Bearing IncI2 Plasmid.
P2860
Q24646623-A0F3F6CA-B2D2-45E2-AF57-D59A27CEF41CQ26749590-72A3180D-E14C-49B3-A2E6-EA8645EB2D94Q28249617-3C2402C6-4A65-45F3-A9D1-421CC7A02A53Q33826293-2654E2E1-D884-4F64-B4CA-C7464A1EDF72Q33962811-6F16662E-CBDC-4F97-A8C4-F56657D43950Q34354019-9EACF6DA-F2A5-4F9C-9E15-1C5080EF2877Q34402134-673D6EC7-5633-4AC9-8F79-18F6EC0E8BFCQ34529235-FFB444C7-B221-4959-A25E-A514822E75D4Q35707946-DAE4623A-3C42-4C46-9C12-80D2226EB2EEQ35960745-904B2D52-983C-4EE4-ACEE-4C917BE107C3Q36448290-896E3393-A2D6-4B40-8EBB-E7DB3FA137D2Q36595848-F2CDB38B-FFB0-4F89-9436-CB96FC8FF62DQ36630989-F68F8F90-3A8F-4E32-ACCD-B4B872CC117FQ37546694-0D3A1564-7B1D-46CA-8C80-9F8F45618752Q38076454-61F206B7-FAB1-451C-ABE6-590C90159AD3Q38626867-FA625FF3-3FD5-46F8-ADA9-D768C7E8F22DQ39919691-9CA904BA-8D56-4D56-8CB0-8C09BAA92EECQ41206521-5E0C91D2-82B0-4DA0-A6C2-AA072DD8A944Q41915492-92379156-15C3-4E19-8922-41F14FC432ADQ42022872-4BE4F6E5-FF6B-48F1-A421-1E6E29A4E05AQ42139092-0DCA5744-15DD-4155-AF2D-2F4FBA621EFEQ42947069-8D8B2F9F-BC6C-4B0C-B509-6C927E952DDCQ45199586-ADD50A5E-6ADF-4307-B407-2753A4DF0771Q47570250-2DDB5CF7-26B3-4C1B-910E-94E44199C397Q48139078-45F10EC2-43DC-4A52-B0DA-4B26F8564499Q49701622-B886BC9C-9FBA-460C-9708-7B76CF5D1828
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
IRT and CMT beta-lactamases and inhibitor resistance.
@en
IRT and CMT beta-lactamases and inhibitor resistance.
@nl
type
label
IRT and CMT beta-lactamases and inhibitor resistance.
@en
IRT and CMT beta-lactamases and inhibitor resistance.
@nl
prefLabel
IRT and CMT beta-lactamases and inhibitor resistance.
@en
IRT and CMT beta-lactamases and inhibitor resistance.
@nl
P2093
P1476
IRT and CMT beta-lactamases and inhibitor resistance.
@en
P2093
E Gomez G de la Pedrosa
M I Morosini
O Martín S de la Maza
P356
10.1111/J.1469-0691.2007.01849.X
P478
14 Suppl 1
P577
2008-01-01T00:00:00Z